Publications by authors named "Margaret C Lunn"
Article Synopsis
- Radioimmunotherapy (RIT) is being explored to enhance treatment for acute leukemia and higher-risk myelodysplastic syndrome (MDS), focusing on alpha-particle emitters like astatine-211 (At) that can kill target cells effectively within a short distance.* -
- Researchers developed murine monoclonal antibodies (mAbs) that specifically target the CD123 antigen, found on acute leukemia and MDS cells, and confirmed that these mAbs could be linked to a boron compound and labeled with At for targeted treatment.* -
- In experiments with immunodeficient mice, the At-labeled anti-CD123 mAbs specifically reduced tumor size and improved survival rates in CD123-positive leukemia models, suggesting that
There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more potent CD33-directed therapeutics.
View Article and Find Full Text PDF